摘要
目的探讨RAD51基因在结直肠癌(CRC)中的表达及其与临床病理特征和预后的关系。方法收集72例CRC患者的病理标本(CRC组,n=72),以及经病理证实无癌细胞存在、距肿瘤边缘>3 cm的肠黏膜组织(癌旁对照组,n=72)。采用qRT-PCR和Western blotting技术对CRC与癌旁组织的RAD51 mRNA和蛋白表达水平进行检测。影响CRC患者预后的因素采用Cox比例风险模型分析。预后分析采用Kaplan-Meier和Log-rank法。结果CRC组RAD51 mRNA和蛋白相对表达量均高于癌旁对照组,差异有统计学意义(P<0.05)。CRC组织中RAD51表达水平与TNM分期有关(P<0.05)。RAD51高表达是影响CRC患者5年无瘤生存率和5年总体生存率的危险因素(P<0.05)。RAD51低表达的CRC患者5年总体生存率和5年无瘤生存率均高于RAD51高表达患者(P<0.05)。结论RAD51在CRC组织中高表达,与TNM分期有关。RAD51高表达的CRC患者预后差,RAD51可能是临床上预测CRC患者预后的一个潜在指标。
Objective To explore the expression of RAD51 gene in colorectal cancer(CRC)and its relationship with clinicopathological features and prognosis.Methods The pathological specimens of 72 CRC patients were collected(CRC group,n=72),as well as the normal intestinal mucosa which was pathologically conformed with no tumor cells and was>3 cm away from the edge of the tumor(control group,n=72).The expression levels of RAD51 mRNA and protein in CRC and adjacent tissues were detected by qRT-PCR and Western blotting.The prognostic factors of CRC patients were analyzed by Cox proportional hazards model.The prognosis was analyzed by Kaplan-Meier and Log-rank methods.Results The relative expression levels of RAD51 mRNA and protein were higher in CRC group than in control group(P<0.05).The expression level of RAD51 in CRC was correlated with TNM stage(P<0.05).The high expression of RAD51 was an independent factor affecting 5-year overall survival rate and 5-year tumor-free survival rate of CRC patients(P<0.05).The 5-year overall survival rate and 5-year tumor-free survival rate of patients with low expression of RAD51 in CRC tissues were higher than those in patients with high expression of RAD51(P<0.05).Conclusion RAD51 was highly expressed in CRC tissues,and it was related with TNM staging.CRC patients with high expression of RAD51 in tissues had poor prognosis.RAD51 may be a potential prognostic indicator for CRC patients.
作者
薛金菊
张艳姣
邢梦芸
XUE Jinju;ZHANG Yanjiao;XING Mengyun(Geriatrics Department,Haikou Affiliated Hospital of Central South University Xiangya School of Medicine,Haikou,570208,Hainan,China)
出处
《肿瘤药学》
CAS
2022年第6期785-790,共6页
Anti-Tumor Pharmacy